Citadel Advisors
PHIO icon

Citadel Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

Citadel Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-194
Closed -$21K – 14340
2021
Q4 		$21K Buy
194
+17
+10% +$2.7K ﹤0.01% 13579
2021
Q3 		$39K Buy
177
+2
+1% +$418 ﹤0.01% 13479
2021
Q2 		$43K Buy
+175
New +$43.1K ﹤0.01% 13389

Other funds holding PHIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Citadel Advisors's PHIO Position: Q1 2025 in Review

Citadel Advisors sold out of Phio Pharmaceuticals (PHIO) in Q1 2025, closing a stake of 44,526 shares — an estimated $80.1K sold.

Citadel Advisors first reported a position in PHIO in Q2 2017 and held it in 12 quarters. The position peaked at $84K in Q2 2021. 11 funds tracked by Wall St. Rank hold PHIO as of Q1 2025.

  • Citadel Advisors reported no remaining Phio Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 44,526 Phio Pharmaceuticals shares in Q1 2025, an estimated $80.1K.
  • Citadel Advisors first reported a position in Phio Pharmaceuticals in Q2 2017 and held it in 12 quarters.
  • Citadel Advisors's Phio Pharmaceuticals position peaked at $84K in Q2 2021.
  • 11 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.